Business Context and Reporting Period
This Form 8-K filing by Halozyme Therapeutics, Inc. reports a corporate governance event dated June 28, 2006. The company is incorporated in Nevada with principal executive offices in San Diego, California. The filing specifically addresses a change in the registrant's certifying accountant.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the transition of the independent registered public accounting firm.
Material Changes
- Dismissal of Prior Accountant: The Audit Committee dismissed Cacciamatta Accountancy Corporation effective immediately on June 28, 2006.
- Engagement of New Accountant: The Audit Committee engaged Ernst & Young, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2006.
- Audit History: Reports issued by Cacciamatta for fiscal years 2004 and 2005 contained no adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- Disagreements: The company reported no disagreements with Cacciamatta on accounting principles, practices, or audit procedures during the relevant periods. No "reportable events" occurred.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of business risks. The only contingency noted is the standard requirement for the former accountant to provide a letter to the SEC confirming the company's statements regarding the dismissal, which was attached as Exhibit 16.1.
Investor Verification Checklist
- Verify the effective date of the new engagement with Ernst & Young, LLP (Fiscal year ending Dec 31, 2006).
- Confirm the absence of any undisclosed disagreements or reportable events with the former auditor, Cacciamatta Accountancy Corporation.
- Review the attached Exhibit 16.1 (Letter from Cacciamatta) to ensure the former accountant concurred with the company's disclosures.
- Note that this filing does not provide updated financial statements; investors should refer to the most recent 10-K or 10-Q for financial data.